News

Such forward-looking statements include statements regarding, among other things, Vera’s anticipated poster presentations at the American Society of Nephrology Kidney Week 2023, and Vera’s ...
BRISBANE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative ...
Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating ataciceptin IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces ...
Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces ...